B3 (Niacin) is widely recognised for its ability to improve skin tone, reduce redness, and support the skins barrier function
Important safety considerations include common adverse effects such as gastrointestinal symptoms (nausea, vomiting, diarrhea), which occur in 20-40% of patients but typically diminish with continued use
These findings suggest a wide safety margin, though absence of long-term human data represents a significant gap
Category lists, enforcement discretion, and the gray zone people keep misreading If youve been tracking peptide news, youve likely seen a recurring claim: FDA removed peptides from Category 2, so theyre allowed again. Thats not how the legal mechanics work
Think of it as preparing the scalp for growth rather than directly stimulating it
Bmj 366, l4898